T1	p 191 206	herpes zoster (
T2	p 216 238	postherpetic neuralgia
T3	p 262 297	individuals > or =60 years of age .
T4	p 464 533	frozen ) in subjects > or =50 years of age . Subjects with a negative
T5	p 639 689	1:2 by age ( 50 to 59 years and > or =60 years ) .
T6	p 1138 1148	frozen ( n
T7	i 98 129	refrigerator-stable formulation
T8	i 133 143	Zostavax .
T9	i 148 164	vaccine Zostavax
T10	i 357 414	refrigerator-stable formulation ( Zostavax refrigerated )
T11	i 453 472	( Zostavax frozen )
T12	i 584 588	dose
T13	i 611 612	.
T14	i 758 765	virus (
T15	i 810 822	glycoprotein
T16	i 851 856	assay
T17	i 867 870	) .
T18	i 998 999	;
T19	i 1084 1087	AEs
T20	i 1109 1121	refrigerated
T21	i 1138 1144	frozen
T22	i 1284 1316	formulation/frozen formulation )
T23	i 1572 1586	injection-site
T24	i 1806 1821	vaccine-related
T25	i 1905 1913	Zostavax
T26	i 2008 2015	vaccine
T27	o 191 209	herpes zoster ( HZ
T28	o 322 328	safety
T29	o 337 351	immunogenicity
T30	o 690 696	Safety
T31	o 739 763	. Varicella-zoster virus
T32	o 770 790	) antibody responses
T33	o 810 822	glycoprotein
T34	o 837 850	immunosorbent
T35	o 902 943	VZV antibody geometric mean titer ( GMT ;
T36	o 959 997	VZV antibody geometric mean rise ( GMR
T37	o 1025 1089	incidence of vaccine-related serious adverse experiences ( AEs )
T38	o 1186 1198	GMTs ( 727.4
T39	o 1249 1270	estimated GMT ratio (
T40	o 1376 1380	GMRs
T41	o 1424 1451	vaccine-related serious AEs
T42	o 1492 1507	safety profiles
T43	o 1569 1590	of injection-site AEs
T44	o 1732 1759	frequencies of systemic AEs
T45	o 1806 1825	vaccine-related AEs
T46	o 1957 1968	immunogenic